Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease

Journal of the American Society of Nephrology

Volumn 14, Issue 6, 2003, Pages 1605-1613

  Tonelli, Marcello ^a   Moyé, Lemuel ^b   Sacks, Frank M ^c   Cole, Thom ^d   Curhan, Gary C ^b,e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAVASTATIN;

ADULT; AGED; ALGORITHM; ARTICLE; CALCULATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0038512398     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000068461.45784.2F     Document Type: Article

References (40)

1. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY: Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 32: 992-999, 1998
2. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330: 877-884, 1994
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
4. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945, 1996
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, the CSG: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
8. Keane WF: The role of lipids in renal disease: Future challenges. Kidney Int 57[Suppl 75]: S27-S31, 2000
9. Kasiske BL, O'Donnell MP, Kim Y, Keane WF: Treatment of hyperlipidemia in chronic progressive renal disease. Curr Opin Nephrol Hypertens 2: 602-608, 1993
10. Guijarro C, Keane WF: Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab 22: 147-152, 1996
11. Garg AX, Blake PG, Clark WF, Clase CM, Haynes RB, Moist LM: Association between renal insufficiency and malnutrition in older adults: Results from the NHANES III. Kidney Int 60: 1867-1874, 2001
12. Kaysen GA: The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 12: 1549-1557, 2001
13. Eikelboom JW, Hankey GJ: Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. Curr Opin Nephrol Hypertens 10: 377-383, 2001
14. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AMJ: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344: 1959-1965, 2001
15. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59: 260-269, 2001
16. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Wamica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001-1009, 1996
17. NKF-K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Am J Kidney Dis 39: S76-S110, 2002
18. Sacks FM, Pfeffer MA, Moye' L, Brown LE, Hamm P, Cole TG, Hawkins CM, Braunwald E: Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE) Am J Cardiol 68: 1436-1446, 1991
19. Westgard JO, Barry PL, Hunt MR, Groth T: A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem 27: 493-501, 1981
20. Mellies MJ, DeVault AR, Kassler-Taub K, McGovern ME, Pan HY: Pravastatin experience in elderly and non-elderly patients. Atherosclerosis 101: 97-110, 1993
21. Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan H: Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 32: 124-132, 1992
22. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976
23. Schluchter MD, Greene T, Beck GJ: Analysis of change in the presence of informative censoring: Application to a longitudinal clinical trial of progressive renal disease. Stat Med 20: 989-1007, 2001
24. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
25. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, Klahr S: Dietary protein restriction and the progression of chronic renal disease: What have all of the results of the MDRD study shown? J Am Soc Nephrol 10: 2426-2439, 1999
26. Fuiano G, Esposito C, Sepe V, Colucci G, Bovino M, Rosa M, Balletta M, Bellinghieri G, Conte G, Cianciaruso B, Canton AD: Effects of hypercholesterolemia of renal hemodynamics: Study in patients with nephrotic syndrome. Nephron 73: 430-435, 1996
27. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95: 1126-1131, 1997
28. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 36: 427-431, 2000
29. Katznelson S, Kobashigawa JA: Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression. Kidney Int Suppl 52: S112-S115, 1995
30. Oda H, Keane WF: Recent advances in statins and the kidney. Kidney Int Suppl 71: S2-S5, 1999
31. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107: 87-92, 2003
32. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD: C-reactive protein and soluble vascular cell adhesion molecule-1 are associated with elevated urinary albumin excretion but do not explain its link with cardiovascular risk. Arterioscler Thromb Vasc Biol 22:593-598, 2002
33. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. Diabetes 51: 1157-1165, 2002
34. Sarnak MJ, Poindexter A, Wang SR, Beck GJ, Kusek JW, Marcovina SM, Greene T, Levey AS: Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int 62: 2208-2215, 2002
35. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K: Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 34: 51-61, 1996
36. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, Levey AS: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis. 39: 920-929, 2002
37. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138: 98-104, 2003
38. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56: 2214-2219, 1999
39. Golan L, Birkmeyer JD, Welch HG: The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 131: 660-667, 1999
40. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S: To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ 162: 195-198, 2000